Proactive Investors - Run By Investors For Investors

AusCann Group shortlists candidates for chief executive officer role

Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board.
growing facility
The company is expected to make an appointment early in the new year

AusCann Group Holdings Ltd’s (ASX:AC8) search for a new chief executive officer is progressing to plan and is now at an advanced stage.

The board has selected a final shortlist and is confident in the high calibre of Australian and international candidates that it believes have the necessary skills and experience to guide AusCann through its next phase of growth as a pharmaceutical manufacturing and sales business.

AusCann is expected to make an appointment once final interviews have been completed early in the new year.

Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board.

READ: AusCann Group appoints Paul MacLeman as executive director

Dr MacLeman is an experienced pharmaceutical executive and has been a senior consultant to AusCann since October 2017. He is leading the board’s executive CEO search process.

AusCann managing director Elaine Darby said: “The CEO search process is progressing very well and is now nearing completion.

“The transition is a natural evolution that reflects the continued growth and development of AusCann, and the board has worked to ensure it is a well planned and orderly one.

READ: AusCann Group appoints PCI Pharma to manufacture first product line

“I am extremely proud of what we have achieved at AusCann since the inception of the company in 2014 and listing in early 2017, including our licensing, cultivation, and product development activities which have culminated into our hard shell capsules soon to be commercialised.

“I am confident AusCann will go from strength to strength as it moves into a manufacturing and marketing footing for our first-generation product range.

“We see innovation and continued new product development as key to the next stages of the company’s development.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

medicinal cannabis concept
January 30 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
cannabis bud on tray
Thu
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
cannabis plan in sun
February 21 2019
The cannabis company will manufacture, infuse and package branded recreational and wellness products
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use